Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
307.01B
Market cap307.01B
Price-Earnings ratio
20.14
Price-Earnings ratio20.14
Dividend yield
2.24%
Dividend yield2.24%
Average volume
2.53M
Average volume2.53M
High today
$150.06
High today$150.06
Low today
$145.30
Low today$145.30
Open price
$148.74
Open price$148.74
Volume
2.02M
Volume2.02M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$97.72
52 Week low$97.72

NVS News

Benzinga 2d
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug

• Novartis stock is taking a breather. What should traders watch with NVS? Novartis Targets Next-Generation Breast Cancer Therapy The deal centers on SNV4818,...

Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug
TipRanks 3d
Novartis Stock Climbs after Paying $3B for “Mutant” Fighting Breast Cancer Drug

Shares in Swiss drugmaker Novartis (NVS) were slightly healthier today after it bought an experimental “mutant”- fighting breast cancer drug from U.S. biotech f...

TipRanks 3d
Novartis to acquire Pikavation Therapeutics from Synnovation Therapeutics

Novartis (NVS) announced that it has entered into an agreement with Synnovation Therapeutics to acquire SNV4818, a pan-mutant-selective PI3Kalpha inhibitor, exp...

Analyst ratings

50%

of 28 ratings
Buy
35.7%
Hold
50%
Sell
14.3%

More NVS News

Seeking Alpha 3d
Novartis to buy experimental breast cancer drug for up to $3B

Novartis (NVS) has agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3B to support its oncology strategy in HR+/HER...

Novartis to buy experimental breast cancer drug for up to $3B
The Wall Street Journal 3d
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

With the deal, the company aims to explore a next-generation approach for the treatment of breast cancer. fabrice coffrini/Agence France-Presse/Getty Images No...

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
TipRanks 4d
Novartis initiated with a Market Perform at Bernstein

Bernstein initiated coverage of Novartis (NVS) with a Market Perform rating and CHF 125 price target The firm sees five years of annual sales declines between 2...

Benzinga 6d
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients

On Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) Cosentyx (secukinumab) for younger patients. The approval covers pediat...

Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.